Testosterone Replacement Therapy Market: Increasing Number of Hypogonadism Patients to Drive the Growth

A range of testosterone replacement therapy (TRT) products formulated from various active ingredients are available in the market these days. At present around 30% of men worldwide suffer from hypogonadism or testosterone deficiency as shown by different studies. The percentage is substantial and in the near future it is slated to spike thereby likely effecting a demand jump for TRT products. The global market for testosterone replacement therapy is highly consolidated with the top five players accounting for a lion’s share – almost 80.0% – of the market.

Request for Sample Copy of Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1097

A report by Transparency Market Research scopes out the global testosterone market by segmenting it by product type and active ingredients. The different TRT products are avinto patches, injections, creams/gels, gums/buccal adhesives, oral drug forms, and implants. The creams/gels segment, among them, accounts for a dominant share in the market due to the robust sales of branded formulations. In terms of growth rate, however, the injections product segment is slated to outshine others with more consumers buying the products as they are relatively cheap and can be self-administered. Among the different active ingredients, testosterone holds a sway over the market but is expected to face strong competition from other active ingredients such as testosterone undecanoate and testosterone cypionate in the upcoming years.

A major concern in the global testosterone replacement therapy market is the imminent patent expiration of some of the top products which will pave the way for lesser priced generics in the market. This is predicted to bring down revenues of dominant players significantly. The segment predicted to take maximum hit is the gels/cream TRT products, which now enjoys a dominant market share because of its ease of use and reduced side effects. Another factor bogging down the market is the possible risk of cardiovascular or metabolic disease resulting from the treatment of testosterone deficiency.

Enquiry for discount on this report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=1097

The blow dealt by the patent expirations to the global market for testosterone replacement therapy is expected to be somewhat mitigated by the growing instances of testosterone deficiency and a burgeoning geriatric population – a key target demographic for companies. Besides, rising awareness about testosterone replacement therapy (TRT) and unveiling of innovative testosterone replacement therapy technology such as spray-on and unmodified testosterone is also expected to propel sales and offset the loss to some extent. But overall, patent expirations will drag down revenues in the long run. The report by Transparency Market Research, finds that revenues in the global market will tumble and reach US$1.3 bn by 2024 from US$2.0 bn in 2015 at a negative CAGR of 4.2% CAGR from 2016 to 2024.

North America, powered by strong demand for advanced TRT products in the U.S., dominates the global testosterone replacement market by accounting for almost 84.0% share in it. In fact, the U.S. occupied about 95.0% of the North America market in 2015. Europe follows North America vis-à-vis market share. Other important markets are Asia Pacific, the Middle East and Africa (MEA), and Latin America. Asia Pacific is expected to exhibit speedy growth because of significantly higher healthcare investments. China and India hold out a solid potential for the TRT market. South Korea and Japan too will impact sales positively due to a growing population of geriatrics. In Latin America, Brazil is the primary TRT market with maximum share.

Report Overview @ https://www.transparencymarketresearch.com/testosterone-replacement-therapy.html

Prominent players in the global testosterone replacement therapy market are Allergan plc, Novartis AG, AbbVie, Inc., Endo Pharmaceuticals, Inc., Bayer AG, Eli Lilly and Company, Mylan N.V., and Pfizer, Inc.

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: https://www.transparencymarketresearch.com

This release was published on openPR.